ReviewArthritis research & therapy2015
Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials.
Review in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03958851 (Measurement of Renal Artery Resistive Index as a Predictor of Severity of Lupus Nephritis and Its Response to Treatment), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Measurement of Renal Artery Resistive Index as a Predictor of Severity of Lupus Nephritis and Its Response to Treatment
Who cites it
18 citing papers in PubMed.
- Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.Lupus science & medicine · 2023Trial
- Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.Annals of the rheumatic diseases · 2022Trial
- Repeat Kidney Biopsy in Lupus Nephritis: Diagnostic Yield and Clinical Utility in a Real-World Single-Centre Cohort.Journal of clinical medicine · 2026Article
- Defining PI3K Signaling as a Key Regulator of Molecular Heterogeneity and Inflammation in Glomerular Lupus Nephritis.Immune network · 2026Article
- Lupus nephritis randomised controlled trials: evidence gaps and under-represented groups.Lupus science & medicine · 2024Article
- Renal response status to predict long-term renal survival in patients with lupus nephritis: results from the Toronto Lupus Cohort.Lupus science & medicine · 2024Observational
- Urine biomarker score captures response to induction therapy with lupus nephritis.Pediatric nephrology (Berlin, Germany) · 2023Article
- Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort.Lupus science & medicine · 2022Article
- Voclosporin: a novel calcineurin inhibitor with no impact on mycophenolic acid levels in patients with SLE.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2022Article
- Initial Preserved Renal Function as a Predictor of Favorable Renal Response to Rituximab in Refractory or Relapsing Lupus Nephritis: A Single-center Cohort Study in Korea.Journal of rheumatic diseases · 2022Article
- Association of explanatory histological findings and urinary protein and serum creatinine levels at renal biopsy in lupus nephritis: a cross-sectional study.BMC nephrology · 2020Article
- Systematic Review and the External Validity of Randomized Controlled Trials in Lupus Nephritis.Kidney international reports · 2018Article
- Lupus community panel proposals for optimising clinical trials: 2018.Lupus science & medicine · 2018Review
- Redefining lupus nephritis: clinical implications of pathophysiologic subtypes.Nature reviews. Nephrology · 2017Review
- Modelling clinical systemic lupus erythematosus: similarities, differences and success stories.Rheumatology (Oxford, England) · 2017Review
- Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsy-proven nephritis?Lupus science & medicine · 2017Article
- What is damaging the kidney in lupus nephritis?Nature reviews. Rheumatology · 2016Review
- Association of Serum CXCL13 with Intrarenal Ectopic Lymphoid Tissue Formation in Lupus Nephritis.Journal of immunology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with diverse manifestations. Although the approval of new therapies includes only one agent in 50 years, a number of promising new drugs are in development. Lupus nephritis is a dreaded complication of SLE as it is associated with significant morbidity and mortality. Advancing the treatment of lupus nephritis requires well-designed clinical trials and this can be challenging in SLE. The major obstacles involve identifying the correct population of patients to enroll and ensuring that a clinically appropriate and patient-centered endpoint is being measured. In this review, we will first discuss the clinical utility of endpoints chosen to represent lupus nephritis in global disease activity scales. Second, we will review completed and active trials focused on lupus nephritis and discuss the endpoints chosen. There are many important lessons to be learned from existing assessment tools and clinical trials. Reviewing these points will help ensure that future efforts will yield meaningful disease activity measures and well-designed clinical trials to advance our understanding of lupus management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.